SOURCE: Sunshine Biopharma Inc.

Sunshine Biopharma Inc.

July 16, 2013 08:00 ET

Sunshine Biopharma Parent Company Awarded Research Grant of $940,000 to Advance Adva-27a Cancer Drug Candidate

MONTREAL--(Marketwired - Jul 16, 2013) - Sunshine Biopharma Inc. (OTCQB: SBFM) is pleased to announce that its parent company, Advanomics Corporation, has been awarded a research grant from the prestigious agencies Natural Sciences and Engineering Research Council of Canada ("NSERC") and NanoQuebec to advance the development of Adva-27a, the Company's flagship oncology compound targeted for multidrug resistant cancers. The grant, in the amount of $940,000, was awarded to Advanomics Corporation in collaboration with Ecole Polytechnique.

In its letter of offer, NSERC states: "The [Advisory] Committee was impressed by the calibre of the research team, the scientific merit of the proposal, and the potential training opportunities."

Adva-27a is Advanomics Corporation's and Sunshine Biopharma's lead anticancer compound, a small molecule that has recently been shown to be effective at killing multidrug resistant breast cancer cells, small-cell lung cancer cells, uterine sarcoma cells and pancreatic cancers cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Adva-27a is currently in the IND-Enabling stage of development. The original US patent covering Adva-27a was issued on August 7, 2012 under US patent number 8,236,935.

"This is a big stamp of approval for Adva-27a," said Dr. Steve N. Slilaty, CEO of Sunshine Biopharma. "Our clinical trials are rapidly approaching and we could not be happier that such distinguished and experienced agencies are impressed by our compound. We are extremely grateful for the dedication and support of NSERC, NanoQuebec and Ecole Polytechnique which dovetails with our goal to develop new therapeutics for cancer."

About Advanomics Corporation
Advanomics Corporation is a privately held Canadian company (55% shareholder of Sunshine Biopharma Inc.) focused on the research and development of treatments for cancer and other human diseases. Advanomics is conducting research and development in the areas of siRNA and Carbon-Difluoride Chemistry to generate novel anticancer compounds.

Safe Harbor Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, future collaboration agreements, the success of the Company's development, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made.

Contact Information